This company listing is no longer active
Biohaven Pharmaceutical Holding Crecimiento futuro
Future controles de criterios 5/6
Información clave
72.7%
Tasa de crecimiento de los beneficios
71.2%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 35.4% |
| Tasa de crecimiento de los ingresos | 29.2% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2024 | 1,977 | -7 | N/A | N/A | 5 |
| 12/31/2023 | 1,330 | -512 | N/A | N/A | 7 |
| 12/31/2022 | 1,081 | -948 | N/A | N/A | 7 |
| 6/30/2022 | 860 | -1,021 | -579 | -556 | N/A |
| 3/31/2022 | 738 | -791 | -650 | -649 | N/A |
| 12/31/2021 | 463 | -847 | -833 | -831 | N/A |
| 9/30/2021 | 308 | -865 | -852 | -850 | N/A |
| 6/30/2021 | 190 | -889 | -832 | -809 | N/A |
| 3/31/2021 | 106 | -859 | -781 | -758 | N/A |
| 12/31/2020 | 64 | -767 | -748 | -703 | N/A |
| 9/30/2020 | 29 | -698 | -638 | -591 | N/A |
| 6/30/2020 | 11 | -609 | -524 | -497 | N/A |
| 3/31/2020 | 1 | -639 | -507 | -481 | N/A |
| 12/31/2019 | N/A | -529 | -381 | -377 | N/A |
| 9/30/2019 | N/A | -434 | -313 | -310 | N/A |
| 6/30/2019 | N/A | -390 | -293 | -289 | N/A |
| 3/31/2019 | N/A | -218 | -167 | -162 | N/A |
| 12/31/2018 | N/A | -241 | -201 | -197 | N/A |
| 9/30/2018 | N/A | -213 | -207 | -204 | N/A |
| 6/30/2018 | N/A | -195 | -179 | -177 | N/A |
| 3/31/2018 | N/A | -202 | -170 | -169 | N/A |
| 12/31/2017 | N/A | -139 | -95 | -95 | N/A |
| 9/30/2017 | N/A | -138 | -70 | -70 | N/A |
| 6/30/2017 | N/A | -123 | -57 | -57 | N/A |
| 3/31/2017 | N/A | -83 | -36 | -36 | N/A |
| 12/31/2016 | N/A | -64 | -30 | -30 | N/A |
| 9/30/2016 | N/A | -42 | -15 | -15 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: 2VN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Beneficios vs. Mercado: 2VN is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: 2VN is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: 2VN's revenue (29.2% per year) is forecast to grow faster than the German market (3.9% per year).
Ingresos de alto crecimiento: 2VN's revenue (29.2% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 2VN's Return on Equity is forecast to be high in 3 years time